Grifols, S.A.

FOXO TECHNOLOGIES INC.’S SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC.

WEST PALM BEACH, FL, July 29, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc.’s (OTC: FOXOD/FOXO) ( “FOXO”) subsidiary, Vector BioSource, Inc. (“Vector”) today announced that it has entered into a definitive agreement to acquire four U.S.-based blood collection centers (the “Agreement”) from Grifols Bio Supplies, Inc., a U.S.-based subsidiary of Grifols S.A. The acquisition is intended to provide a proprietary source of bio-products to sell to Vector’s customers to augment its existing sourcing

Yahoo Finance · 29/07/2026 · lire l'article ↗

Grifols (GRFS) Q2 2026 Earnings Call Transcript

CEO Abia discusses immunoglobulin growth and Egypt plasma expansion strategy.

Yahoo Finance · 29/07/2026 · lire l'article ↗

Grifols SA (GRFS) (H1 2026) Earnings Call Highlights: Strong Biopharma Growth and Strategic ...

Grifols SA (GRFS) reports robust revenue growth and strategic progress, despite facing temporary challenges in key markets.

Yahoo Finance · 29/07/2026 · lire l'article ↗

Grifols Q2 Earnings Call Highlights

Grifols (NASDAQ:GRFS) said its second-quarter and first-half results kept the plasma-derived medicines company on track to meet its 2026 objectives, supported by continued growth in immunoglobulins, improving free cash flow and progress in its plasma-sourcing strategy. Chief Executive Officer Nacho

Yahoo Finance · 28/07/2026 · lire l'article ↗

Grifols (BME:GRF) Starts Phase 3 Trials As Undervalued Narrative Faces A Fresh Test

Grifols (BME:GRF) has started dosing patients in two Phase 3 trials for its immunoglobulin therapies, GAMUNEX-C and XEMBIFY, aiming to expand their U.S. labels and potentially broaden future treatment options. See our latest analysis for Grifols. These new Phase 3 trials come as Grifols shares trade at €9.85, with a 90 day share price return of 10.36% but a year to date share price return that has declined 12.05%, and a 1 year total shareholder return that has fallen 19.51%. This suggests...

Yahoo Finance · 28/07/2026 · lire l'article ↗

Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins

One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX®-C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patients with secondary immunodeficiencyA second trial, XPERT, will determine whether Grifols’ subcutaneous Ig, XEMBIFY® (immune globulin subcutaneous human klhw) is non-inferior to GAMUNEX-C in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)Both studies are designed to supp

Yahoo Finance · 16/07/2026 · lire l'article ↗